JP2010518128A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518128A5
JP2010518128A5 JP2009549348A JP2009549348A JP2010518128A5 JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5 JP 2009549348 A JP2009549348 A JP 2009549348A JP 2009549348 A JP2009549348 A JP 2009549348A JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
independently
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000293 external-priority patent/WO2008098368A1/en
Publication of JP2010518128A publication Critical patent/JP2010518128A/ja
Publication of JP2010518128A5 publication Critical patent/JP2010518128A5/ja
Pending legal-status Critical Current

Links

JP2009549348A 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター Pending JP2010518128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89030407P 2007-02-16 2007-02-16
PCT/CA2008/000293 WO2008098368A1 (en) 2007-02-16 2008-02-15 Inhibitors of hepatitis c ns3 protease

Publications (2)

Publication Number Publication Date
JP2010518128A JP2010518128A (ja) 2010-05-27
JP2010518128A5 true JP2010518128A5 (enExample) 2011-04-07

Family

ID=39689592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549348A Pending JP2010518128A (ja) 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター

Country Status (5)

Country Link
US (1) US20100087382A1 (enExample)
EP (1) EP2125870A4 (enExample)
JP (1) JP2010518128A (enExample)
CA (1) CA2676297A1 (enExample)
WO (1) WO2008098368A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP2160392A2 (en) * 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
AU2010253790A1 (en) 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新しい大環状阻害剤
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
BR112012022125A2 (pt) * 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
CA2936749C (en) 2010-06-11 2019-07-09 Joshua R. Giguere Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
HRP20161694T1 (hr) 2012-10-19 2017-03-10 Bristol-Myers Squibb Company 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2979527A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
CN115806518A (zh) * 2022-12-29 2023-03-17 南京安伦化工科技有限公司 一种N-Boc-4-氧代-脯氨酸甲酯的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000085A1 (en) * 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
JP2010518128A5 (enExample)
JP2012526728A5 (enExample)
JP2013523765A5 (enExample)
JP2009504772A5 (enExample)
JP2015500843A5 (enExample)
JP2013537905A5 (enExample)
JP2017523169A5 (enExample)
JP2016006118A5 (enExample)
JP2012524055A5 (enExample)
JP2010535785A5 (enExample)
JP2011520815A5 (enExample)
JP2018135343A5 (enExample)
JP2012092103A5 (enExample)
JP2016518437A5 (enExample)
JP2013503846A5 (enExample)
JP2017510610A5 (enExample)
JP2013545818A5 (enExample)
JP2014513954A5 (enExample)
JP2013538230A5 (enExample)
JP2013537203A5 (enExample)
JP2013545817A5 (enExample)
JP2015522036A5 (enExample)
JP2013542261A5 (enExample)
JP2013544860A5 (enExample)
JP2009525287A5 (enExample)